Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia

被引:549
作者
Matias, Isabel
Gonthier, Marie-Paule
Orlando, Pierangelo
Martiadis, Vassilis
De Petrocellis, Luciano
Cervino, Cristina
Petrosino, Stefania
Hoareau, Laurence
Festy, Franck
Pasquali, Renato
Roche, Regis
Maj, Mario
Pagotto, Uberto
Monteleone, Palmiero
Di Marzo, Vincenzo
机构
[1] CNR, Endocannabinoid Res Grp, Inst Biomol Chem, I-80078 Pozzuoli, NA, Italy
[2] CNR, Inst Biochem Prot, I-80078 Pozzuoli, NA, Italy
[3] CNR, Inst Cybernet, I-80078 Pozzuoli, NA, Italy
[4] Univ La Reunion, F-97715 La Reunion, France
[5] Univ Naples 2, Dept Psychiat, I-80138 Naples, Italy
[6] Univ Bologna, Dept Internal Med & Gastroenterol, Ctr Appl Biomed Res, S Orsola Malpighi Gen Hosp, I-40138 Bologna, Italy
关键词
D O I
10.1210/jc.2005-2679
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Cannabinoid CB1 receptor blockade decreases weight and hyperinsulinemia in obese animals and humans in a way greatly independent from food intake. Objective: The objective of this study was to investigate the regulation and function of the endocannabinoid system in adipocytes and pancreatic beta-cells. Design, Setting, and Patients: Mouse 3T3-F442A adipocytes and rat insulinoma RIN-m5F beta-cells, pancreas and fat from mice with diet-induced obesity, visceral and sc fat from patients with body mass index equal to or greater than 30 kg/m(2), and serum from normoglycemic and type 2 diabetes patients were studied. Main Outcome Measure: Endocannabinoid enzyme and adipocyte protein expression, and endocannabinoid and insulin levels were measured. Results: Endocannabinoids are present in adipocytes with levels peaking before differentiation, and in RIN-m5F beta-cells, where they are under the negative control of insulin. Chronic treatment of adipocytes with insulin is accompanied by permanently elevated endocannabinoid signaling, whereas culturing of RIN-m5F beta-cells in high glucose transforms insulin down-regulation of endocannabinoid levels into up-regulation. Epididymal fat and pancreas from mice with diet-induced obesity contain higher endocannabinoid levels than lean mice. Patients with obesity or hyperglycemia caused by type 2 diabetes exhibit higher concentrations of endocannabinoids in visceral fat or serum, respectively, than the corresponding controls. CB1 receptor stimulation increases lipid droplets and decreases adiponectin expression in adipocytes, and it increases intracellular calcium and insulin release in RIN-m5F beta-cells kept in high glucose. Conclusions: Peripheral endocannabinoid overactivity might explain why CB1 blockers cause weight-loss independent reduction of lipogenesis, of hypoadiponectinemia, and of hyperinsulinemia in obese animals and humans.
引用
收藏
页码:3171 / 3180
页数:10
相关论文
共 38 条
[1]  
[Anonymous], DET EV TREATM HIGH B
[2]  
[Anonymous], LIPIDS HLTH DIS
[3]   The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells [J].
Bensaid, M ;
Gary-Bobo, M ;
Esclangon, A ;
Maffrand, JP ;
Le Fur, G ;
Oury-Donat, F ;
Soubrié, P .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :908-914
[4]  
Berrendero F, 1999, SYNAPSE, V33, P181, DOI 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO
[5]  
2-R
[6]  
Chambers AP, 2004, PHYSIOL BEHAV, V82, P863, DOI 10.1016/S0031-9384(04)00302-6
[7]   Appetite suppression and weight loss after the cannabinoid antagonist SR141716 [J].
Colombo, G ;
Agabio, R ;
Diaz, G ;
Lobina, C ;
Reali, R ;
Gessa, GL .
LIFE SCIENCES, 1998, 63 (08) :PL113-PL117
[8]  
Cota D, 2003, J CLIN INVEST, V112, P423, DOI [10.1172/JCI200317725, 10.1172/JCI17725]
[9]   Adiponectinemia in visceral obesity:: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men [J].
Côté, M ;
Mauriège, P ;
Bergeron, J ;
Alméras, N ;
Tremblay, A ;
Lemieux, I ;
Després, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1434-1439
[10]   Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia [J].
Despres, JP ;
Golay, A ;
Sjostrom, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2121-2134